Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioTTT001 with neoadjuvant therapy in locally advanced breast cancer
NCT07150767Phase 1Withdrawn
- Sponsor
- Beijing Bio-Targeting Therapeutics
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BioTTT001 in breast cancer, sponsored by Beijing Bio-Targeting Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 21 days and Adverse Events at 21 days. Planned start Mar 2025; status: withdrawn.
02
Drugs
BioTTT001
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07150767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150767.